Does COVID-19 Infection Increase the Risk of Pulmonary Embolism?
1 other identifier
observational
347
1 country
1
Brief Summary
The World Health Organization (WHO) declared the 2019 novel coronavirus (COVID-19) a pandemic on March 11, 2020. As of 19 July 2020, there have been 14.3 million confirmed cases and over 600,000 confirmed deaths. Up to 14% of infected patients develop interstitial pneumonia, which may evolve to acute respiratory distress syndrome. COVID-19 associated pulmonary arterial microthrombosis and coagulopathy has prompted physicians to implicate pulmonary embolism (PE) as a potential cause for acute respiratory deterioration. Literature review reveals few studies of varying size, quality and design. Recent meta-analysis reports venous thromboembolism in approximately 20% of COVID-19 patients. There has yet to be a case-controlled study which proves and quantifies the associated between COVID-19 and PE.Confirming and quantifying this association has numerous clinical implications for the treatment of critically unwell patients with COVID-19 infection. For example, clinicians will be more inclined to investigate and treat sudden deteriorations with the knowledge that pulmonary embolism is the commonest cause for said deteriorations.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 19, 2020
CompletedStudy Start
First participant enrolled
January 1, 2021
CompletedFirst Posted
Study publicly available on registry
January 6, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 3, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 3, 2022
CompletedMay 19, 2026
May 1, 2026
1.2 years
November 19, 2020
May 14, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of pulmonary embolism cases related to COVID-19.
109 days
Secondary Outcomes (2)
Severity, distribution of pulmonary embolism as determined by calculated Qanadli score.
109 days
Presence of right heart strain associated with pulmonary embolism.
109 days
Study Arms (2)
Pulmonary Embolism Positive
As determined by CT Pulmonary Angiogram
Pulmonary Embolism Negative
As determined by CT Pulmonary Angiogram
Interventions
Exposure: Positive COVID-19 infection as determined by RT-PCR
Exposure: Negative COVID-19 infection as determined by RT-PCR
Eligibility Criteria
Acute hospital inpatients
You may qualify if:
- Patients who had a CT pulmonary angiogram at NHS Grampian between 3rd March and 20th June 2020.
You may not qualify if:
- Patients with no COVID-19 RT-PCR test done within 7 days of the CT pulmonary angiogram or the same clinical episode.
- Duplicate CT pulmonary angiograms.
- Patients who are already known to have a pulmonary embolism.
- Patients who had radiologically inadequate CT pulmonary angiograms.
- Patients younger than 16 years old.
- Patients who have incomplete or unavailable notes.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Aberdeen Royal Infirmary
Aberdeen, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 19, 2020
First Posted
January 6, 2021
Study Start
January 1, 2021
Primary Completion
March 3, 2022
Study Completion
March 3, 2022
Last Updated
May 19, 2026
Record last verified: 2026-05